New COVID-19 vaccine candidate tested alone or as a booster with mRNA shots

NCT ID NCT07655180

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Invivyd, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new COVID-19 vaccine called VYD2311, given alone or together with an existing mRNA COVID-19 vaccine, in healthy adults aged 18 to 49. The goal is to check safety and measure the body's virus-fighting antibody levels. Participants receive one injection and are monitored for side effects and immune responses over 56 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VYD2311 (a COVID-19 vaccine) and a COVID-19 mRNA vaccine
What this could lead to: If successful, this could lead to a new COVID-19 vaccine option that may be given alone or alongside existing mRNA vaccines to boost protection.
What could go wrong: This is a phase 3 trial, but results may not confirm strong protection against all variants. Side effects like injection site reactions or systemic symptoms are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Invivyd Investigative Site
RECRUITING

Overland Park, Kansas, 66212, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.